Download presentation
Presentation is loading. Please wait.
Published byEgbert Norton Modified over 6 years ago
1
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial Josep M. Grinyó, MD, PhD, Maria del Carmen Rial, MD, PhD, Josefina Alberu, MD, Steven M. Steinberg, MD, Roberto C. Manfro, MD, PhD, Georgy Nainan, MD, Flavio Vincenti, MD, Charlotte Jones-Burton, MD, MS, Nassim Kamar, MD, PhD American Journal of Kidney Diseases Volume 69, Issue 5, Pages (May 2017) DOI: /j.ajkd Copyright © 2016 The Authors Terms and Conditions
2
Figure 1 Mean estimated glomerular filtration rate (eGFR) from month 1 to month 36. Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor. American Journal of Kidney Diseases , DOI: ( /j.ajkd ) Copyright © 2016 The Authors Terms and Conditions
3
Figure 2 Probability of acute rejection. Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor. American Journal of Kidney Diseases , DOI: ( /j.ajkd ) Copyright © 2016 The Authors Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.